Published in Cancer Weekly, April 5th, 2005
Orphan drug status is granted by the EC to promote development of drugs to treat rare diseases or conditions. Orphan drug designation in the European Union may provide several benefits, including 10 years' marketing exclusivity throughout Europe for the therapeutic indication for which it was granted,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.